HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer AG

www.bayer.com

Latest From Bayer AG

Staying Diversified, Bayer Sees Opportunities In Digital Innovation

Despite its Monsanto woes, Bayer is sticking with its diversified portfolio, and is branching out into patient-facing digital health services.

Commercial Digital Health

Korean Biotech Sentiment Still Shaky But IPO Recovery Seen By Year-End

After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.
South Korea Financing

England’s NICE Backs Epidyolex For Seizures, Sativex For MS Spasticity

Health technology assessment body NICE has given the thumbs-up to Epidyolex and Sativex, which become the first plant-derived medicinal cannabis products to secure routine NHS funding. It has also issued positive guidance on other products including nabilone, but turned down the use of cannabis-based drugs in chronic pain.

United Kingdom Reimbursement

GW Gets Two Cannabis-Based Meds Backed By NICE

Two cannabis-based drugs developed by GW Pharmaceuticals have been approved for use on the NHS in England for the first time and will be prescribed to patients with epilepsy and multiple sclerosis.
Neurology Health Technology Assessment
See All

Company Information

UsernamePublicRestriction

Register